Arno Therapeutics (ARNI) Stock Price, News & Analysis

Company Overview

Arno Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for oncology and infectious diseases. The company pursues a licensing and acquisition strategy, in‐licensing promising drug candidates from academic institutions and biotech partners to advance through preclinical and early‐stage clinical trials. Arno’s research model emphasizes repurposing well‐characterized compounds to streamline development timelines and de‐risk regulatory pathways.

The company’s lead program, AR-12, is an autophagy‐modulating small molecule originally licensed from The Ohio State University. AR-12 has demonstrated preclinical activity against multiple solid tumor types and shows potential as a broad‐spectrum antiviral agent. In parallel, Arno is advancing a second candidate, AR-24, a photodynamic therapy agent that leverages tumor‐selective accumulation of prodrugs for both fluorescence‐guided imaging and localized cytotoxicity. Both programs are designed to address high‐unmet medical needs in oncology while offering differentiated mechanisms of action.

Headquartered in Tampa, Florida, Arno Therapeutics collaborates with contract research organizations, academic centers and regulatory advisors across North America and Europe. The company’s agile operational footprint enables cost‐effective preclinical studies and expedited IND‐enabling activities. Strategic partnerships with university laboratories further support biomarker development and translational research efforts, positioning Arno to move its candidates into clinical trials efficiently.

Arno is led by Chief Executive Officer David E. Gil, who brings over 25 years of pharmaceutical development experience, and Chief Financial Officer Glen L. Mallery, a seasoned biotech finance executive. The company’s board and management team combine regulatory expertise, clinical operations know-how and commercial insight to guide Arno’s programs toward key regulatory milestones and potential commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 8,820 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARNI Stock Analysis - Frequently Asked Questions

How do I buy shares of Arno Therapeutics?

Shares of ARNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arno Therapeutics investors own include Ampliphi Biosciences (APHB), Armata Pharmaceuticals (ARMP), Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and Abacus Property Group (ABP).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ARNI
• CIK: 1195116
• Web: www.arnothera.com
• Phone: (503) 598-6659
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A